Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Programmed cell death protein 1 (PDCD1, PD-1) is an immune c...
| Class:Id | Summation:9685298 |
|---|---|
| _displayName | Programmed cell death protein 1 (PDCD1, PD-1) is an immune c... |
| _timestamp | 2020-04-23 10:30:55 |
| created | [InstanceEdit:9685299] Jassal, Bijay, 2020-04-23 |
| modified | [InstanceEdit:9685347] Jassal, Bijay, 2020-04-23 |
| text | Programmed cell death protein 1 (PDCD1, PD-1) is an immune checkpoint protein that guards against autoimmunity. It is a cell-surface protein expressed on T cells and pro-B cells. PDCD1 inhibitors are a group of checkpoint inhibitor drugs that block the activity of PDCD1 present on the surface of these cells. They are mainly used in the treatment of various cancers. Cemiplimab (Libtayo, REGN-2810) is the first FDA approval of a drug specifically for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) (Burova et al. 2017, Migden et al. 2018). Nivolumab (Opdivo) is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor 1 (PD1) (Tan et al. 2017) indicated for many cancers (Yaghoubi et al. 2019). Camrelizumab (SHR-1210) is a fully human anti-programmed cell death 1 (PD1) monoclonal antibody being developed as an immuno-oncology therapeutic (Markham & Keam 2019). Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 is evaluated in clinical trial NCT04268537. |
| (summation) | [Reaction:9679421] PDCD1 binds PDCD1 inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Programmed cell death protein 1 (PDCD1, PD-1) is an immune c... (9685298)
